NR-55615来自SARS相关冠状病毒2的刺突糖蛋白(稳定）,B.1.1.1谱系,带有C末端组氨酸和Avi标签,来自HEK293细胞(蛋白质）的重组
产品图片
货号/SKU
NR-55615
货号/规格
EA
库存与交货期
3-8周
人民币价格
14000
试剂海关审批
A/B级风险物质只能直接使用人购买并持有实验室有效资质，其它询客服确认
国外采购
支持/部分限制一年内购买数量
厂牌
BEI Resources(ATCC)
产品基础信息
生物安全等级建议分类：美国、1
产品描述信息
NR-55615?? Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, B.1.1.1 Lineage with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells(Proteins)|SARS-Related Coronavirus 2|Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, B.1.1.1 Lineage with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells|-20°C or colder|BEI ResourcesAcknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, B.1.1.1 Lineage with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells, NR-55615.”|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
A recombinant form of the spike (S) glycoprotein from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), B.1.1.1 lineage was produced in human embryonic kidney HEK293 cells and purified by immobilized metal affinity chromatography. NR-55615 lacks the signal sequence and contains 1189 residues (ectodomain) of the SARS-CoV-2 S glycoprotein; the recombinant protein was stabilized by substitution at the furin S1/S2 cleavage site (RRAR→GSAS; residues 682 to 685) and KV→PP mutations (residues 986 and 987; wild type numbering), and includes a T4 foldon trimerization domain, HRV3C protease cleavage site and C-terminal octa-histidine tag fused to an AviTag? BirA biotinylation acceptor sequence. NR-55615 includes G75V, T76I, del246-252 (RSYLTPG), D253N, L452Q, F490S, D614G and T859N mutations in the S glycoprotein as compared to the SARS-CoV-2 reference sequence (GenPept: QHD43416). NR-55615 has a theoretical molecular weight of 138,900 daltons. The crystal structure for trimeric S glycoprotein from SARS-CoV-2 has been solved at 3.46 ? resolution (PDB: 6VSB).
The S glycoprotein mediates viral binding to the host angiotensin converting enzyme 2 (ACE2). This protein forms a trimer, and when bound to a host receptor allows fusion of the viral and cellular membranes. The B.1.1.1 lineage includes the sublineage C.37, designated Lambda by the World Health Organization (WHO) and first identified in Peru. The B.1.1.1 lineage is characterized by a novel deletion (del246-252) and mutations including L452Q and F490S in the S glycoprotein Receptor Binding Domain (RBD). These deletions and mutations may contribute to increased transmissibility.
Each vial contains approximately 100 ?L of NR-55615 in 10 mM HEPES, pH 7, 150 mM NaCl and 2 mM ethylenediamine-tetraacetic acid (EDTA).
Additional information and tools are available at ViPR (Virus Pathogen Resource).
A recombinant form of the spike (S) glycoprotein from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), B.1.1.1 lineage was produced in human embryonic kidney HEK293 cells and purified by immobilized metal affinity chromatography. NR-55615 lacks the signal sequence and contains 1189 residues (ectodomain) of the SARS-CoV-2 S glycoprotein; the recombinant protein was stabilized by substitution at the furin S1/S2 cleavage site (RRAR→GSAS; residues 682 to 685) and KV→PP mutations (residues 986 and 987; wild type numbering), and includes a T4 foldon trimerization domain, HRV3C protease cleavage site and C-terminal octa-histidine tag fused to an AviTag? BirA biotinylation acceptor sequence. NR-55615 includes G75V, T76I, del246-252 (RSYLTPG), D253N, L452Q, F490S, D614G and T859N mutations in the S glycoprotein as compared to the SARS-CoV-2 reference sequence (GenPept: QHD43416). NR-55615 has a theoretical molecular weight of 138,900 daltons. The crystal structure for trimeric S glycoprotein from SARS-CoV-2 has been solved at 3.46 ? resolution (PDB: 6VSB).
The S glycoprotein mediates viral binding to the host angiotensin converting enzyme 2 (ACE2). This protein forms a trimer, and when bound to a host receptor allows fusion of the viral and cellular membranes. The B.1.1.1 lineage includes the sublineage C.37, designated Lambda by the World Health Organization (WHO) and first identified in Peru. The B.1.1.1 lineage is characterized by a novel deletion (del246-252) and mutations including L452Q and F490S in the S glycoprotein Receptor Binding Domain (RBD). These deletions and mutations may contribute to increased transmissibility.
Each vial contains approximately 100 ?L of NR-55615 in 10 mM HEPES, pH 7, 150 mM NaCl and 2 mM ethylenediamine-tetraacetic acid (EDTA).
Additional information and tools are available at ViPR (Virus Pathogen Resource).
主要内容
此项目的每个订单数量限制为1.此商品每年可订购两次.此限制的订单将在发货前发送到NIAID批准.
来自重症急性呼吸综合征相关的冠状病毒2（SARS-COV-2），B.1.1.1谱系在人胚胎肾HEK293细胞中产生的重组形式，B.1.1.1.通过固定化金属亲和层析纯化. NR-55615缺乏信号序列，并含有1189个残基（Ectodomain）的SARS-COV-2 S糖蛋白;通过在Furin S1 / S2切割位点（RrAr→GSAs;残基682至685）和KV→PP突变（残留物986和987;野生型编号），并包括T4 Folcon三聚化结构域，HRV3C，通过取代重组蛋白质蛋白酶切割位点和C末端Octa-组氨酸标签与Avitag?Bira Biotinylation受体序列融合. NR-55615包括G75V，T76I，Del246-252（rsyltpg），D253N，L452Q，F490S，D614G和
与SARS-COV-2参考序列相比（Genpept：）相比，s糖蛋白中的T859N突变. . NR-55615具有138,900道尔顿的理论分子量. SARS-COV-2的三聚糖蛋白的晶体结构已在3.46?分辨率（PDB： 6vsb ）中得到解决.
S糖蛋白介导与宿主血管紧张素转化酶2（ACE2）的病毒结合.该蛋白质形成三聚体，并且当与宿主受体结合时，允许融合病毒和细胞膜. B.1.1.1谱系包括Sublineage C.37，由世界卫生组织（WHO）指定Lambda，并在秘鲁中首先确定. B.1.1.1谱系的特征在于一种新的缺失（Del 246-252）和包括S糖蛋白受体结合结构域（RBD）中的L452Q和F490S的突变.这些缺失和突变可能有助于增加传播性.
每个小瓶在10mM HEPES，pH 7,150mM NaCl和2mM乙二胺 - 四乙酸（EDTA）中含有约100μl的NR-55615.
vipr （病毒病原体资源）提供了附加信息和工具.
厂牌介绍
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立，旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中，可以监控科学界对这些材料的访问和使用，并确保试剂的质量控制。
除了为传染病界提供材料外，BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势，包括安全存储、社区访问和分发；同时保护存款人的知识产权。只要有需要，BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月， ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料，包括由其他政府支持的研究项目存放的材料，将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中，涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。
品牌标识
可能感兴趣的内容
2022-04-01
2022-04-01
2021-12-21
2024-09-22
2022-04-01
2024-10-20
2021-12-21
2022-03-31
2024-05-19
2022-04-01
2021-12-13
2024-06-25
2022-04-01